SLRX insider filings
Salarius Pharmaceuticals, Inc. — 13 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-01-02. Screen SLRX transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for SLRX between 2026-07-10 and 2026-10-08. The table below lists the most recent filings on record.
Recent insider filings — Salarius Pharmaceuticals, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-01-02 | 4 | HANISH ARNOLD C — Director | Sale (S): 15 @ $0.64 · Sale (S): 12 @ $0.64 | EDGAR |
| 2025-11-24 | 4 | HANISH ARNOLD C — Director | Purchase (P): 5,000 @ $0.75 | EDGAR |
| 2025-11-20 | 4 | Rosenblum Mark J — Exec VP Finance, CFO | Purchase (P): 20,000 @ $0.80 | EDGAR |
| 2024-04-12 | 4 | Arthur David J. — Chief Executive Officer, Director | Grant/award (A): 20,500 (derivative) @ $0 | EDGAR |
| 2024-02-22 | 4 | McVicar William K. — Director | Grant/award (A): 20,500 (derivative) @ $0 | EDGAR |
| 2024-02-22 | 4 | McCreedy Bruce J Jr. — Director | Grant/award (A): 20,500 (derivative) @ $0 | EDGAR |
| 2024-02-22 | 4 | Burleson Tess — Director | Grant/award (A): 20,500 (derivative) @ $0 | EDGAR |
| 2024-02-22 | 4 | Lammers Paul — Director | Grant/award (A): 20,500 (derivative) @ $0 | EDGAR |
| 2024-02-22 | 4 | Lieber Jonathan I — Director | Grant/award (A): 20,500 (derivative) @ $0 | EDGAR |
| 2024-02-22 | 4 | Rosenblum Mark J — Exec VP Finance, CFO | Grant/award (A): 22,500 (derivative) @ $0 | EDGAR |
| 2024-02-22 | 4 | HANISH ARNOLD C — Director | Grant/award (A): 20,500 (derivative) @ $0 | EDGAR |
| 2023-02-15 | 4 | Arthur David J. — Chief Executive Officer, Director | Grant/award (A): 14,300 @ $0 | EDGAR |
| 2023-02-15 | 4 | Rosenblum Mark J — Exec VP Finance, CFO | Grant/award (A): 6,432 @ $0 | EDGAR |
Recent 8-K events — Salarius Pharmaceuticals, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-23 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-15 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-07-15 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-06-29 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-19 | 8-K | ? 8.01 — Other Events | EDGAR |
| 2026-04-02 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-05 | 8-K | 3.03 — Material Modification to Rights of Security Holders 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-25 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-01-08 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-02 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
Registration filings — Salarius Pharmaceuticals, Inc.
Securities Act registration lifecycles tracked for this issuer (live-forward since 2026-08-01), threaded by SEC file number.
- SEC file 333-299353 (S-1) — latest: Initial registration (S-1), filed 2026-10-07
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=SLRX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →